Welcome to our dedicated page for Surrozen Common news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen Common stock.
Surrozen, Inc. (Nasdaq: SRZN) is a clinical-stage biotechnology firm based in South San Francisco, focused on pioneering regenerative medicine. The company leverages its proprietary technologies to selectively activate the Wnt signaling pathway, a crucial mediator of tissue repair and regeneration. Founded by esteemed scientists from Stanford University, Surrozen aims to unlock the body's self-renewal capabilities through innovative therapeutic approaches.
The company's product pipeline includes several promising candidates:
- SZN-043: Surrozen's lead candidate, SZN-043, uses the company's SWEETS™ technology to treat severe liver diseases, specifically alcohol-associated hepatitis. Following a successful Phase 1a trial that demonstrated safety and target engagement, the company has initiated a Phase 1b clinical trial, with proof-of-concept data anticipated by mid-2025.
- SZN-413: Developed for retinal vascular-associated diseases, SZN-413 leverages Surrozen's SWAP™ technology. Preclinical models have shown that SZN-413 can stimulate Wnt signaling in the eye, potentially inducing normal retinal vessel regrowth. The company has partnered with Boehringer Ingelheim for further research and development, with milestone payments potentially reaching $587.0 million.
Surrozen's strategic direction also includes a strong focus on severe eye diseases and potential applications in other tissues such as the lung and kidney. The company recently published data indicating the potential of Wnt mimetic technologies to treat idiopathic pulmonary fibrosis.
With $43.4 million in cash, cash equivalents, and marketable securities as of September 2023, Surrozen is well-positioned financially to continue its innovative research and clinical trials. The company emphasizes transparency and forward-looking statements, promising continued updates as they advance their clinical programs.
For more details about career opportunities and their latest news, please visit Surrozen's official website.
Surrozen (Nasdaq: SRZN) published results indicating that its proprietary Wnt mimetic antibody, SZN-1326, demonstrated significant potential for treating inflammatory bowel disease (IBD). The study, published in Cellular and Molecular Gastroenterology and Hepatology, utilized a mouse model and showed that SZN-1326 effectively repaired injured colon epithelium while sparing healthy tissue. With no current therapies targeting epithelial repair, Surrozen is set to initiate Phase 1 clinical trials for SZN-1326 in Q3 2022, addressing a notable medical need in ulcerative colitis management.
Surrozen, Inc. (Nasdaq: SRZN) announced financial results for Q1 2022 and provided an update on its clinical pipeline. The company is set to initiate Phase 1 clinical trials for its lead product candidates, SZN-1326 targeting moderate to severe ulcerative colitis and SZN-043 for severe alcoholic hepatitis, in Q3 2022. Both candidates demonstrated substantial efficacy in preclinical trials without adverse effects. Surrozen is also advancing SZN-413 for retinal vascular diseases, with promising preclinical data supporting its potential. The firm remains focused on transitioning to a clinical-stage organization.
Surrozen, a biotechnology company focused on the Wnt pathway for tissue repair, announced that CEO Craig Parker will present at the BofA Securities 2022 Healthcare Conference on May 11 at 4 p.m. PT. The event will be available via a live audio webcast on Surrozen's Investor Relations website, with an archived version accessible later. Surrozen is developing targeted drug candidates for conditions such as inflammatory bowel disease and hearing loss, among others. For more details, visit Surrozen's official website.
Surrozen (Nasdaq: SRZN) announced promising preclinical data for its novel SZN-413, which targets retinal vascular diseases like diabetic retinopathy. Presented at the ARVO Annual Meeting, the data shows SZN-413 significantly reduced pathological neovascular tuft formation and avascular area in mouse models. Additionally, it demonstrated an ~80% reduction in retinal vascular leakage in rabbit models. This progress suggests a new therapeutic strategy in addressing retinal issues caused by diabetes, highlighting the potential of Wnt signaling in regenerative therapies.
Surrozen, Inc. (Nasdaq: SRZN) is advancing its lead therapeutic candidates, SZN-1326 and SZN-043, aimed at treating moderate to severe ulcerative colitis and severe alcoholic hepatitis, respectively. The company expects to initiate Phase 1 clinical trials in healthy volunteers by Q3 2022. SZN-1326 has shown promise in preclinical models for intestinal regeneration, while SZN-043 targets liver function improvement. Additionally, Surrozen continues to broaden its therapeutic pipeline with new candidates targeting vascular-associated retinopathies and potential therapies for dry eye and lung diseases.
Surrozen (Nasdaq: SRZN) has announced the initiation of Phase 1 clinical trials for its lead candidates, SZN-1326 and SZN-043, expected in Q3 2022. The company is also accelerating its research pipeline, including the nomination of SZN-413 for treating retinopathies. SZN-1326 aims to treat moderate to severe ulcerative colitis, while SZN-043 targets severe alcoholic hepatitis. Surrozen's proprietary technologies focus on Wnt pathway modulation for tissue repair, advancing into new therapeutic areas such as ophthalmology.
Surrozen, Inc. (Nasdaq: SRZN) announced plans to present a business update on January 13, 2022, at 9 a.m. ET during the 40th J.P. Morgan Healthcare Conference. The virtual presentation will cover advancements in its pipeline, focusing on drug candidates targeting the Wnt pathway for tissue repair and regeneration. Surrozen is developing specific antibodies for various conditions, including inflammatory bowel disease and neurological disorders. The presentation will be accessible via the Company's Investor Relations website.
Surrozen, Inc. (Nasdaq: SRZN) reported its Q3 2021 financial results, marking a pivotal year as the company began trading publicly. Key highlights include plans for Phase 1 clinical trials for SZN-1326 and SZN-043 in 2022, targeting ulcerative colitis and alcoholic hepatitis. Surrozen's cash position improved to $135.4 million, while research and development expenses rose to $10.4 million for Q3 2021 due to increased external costs. Despite this, the company reported a net loss of $14.0 million for the quarter, compared to $8.6 million in Q3 2020.
Surrozen (Nasdaq: SRZN) has presented encouraging data from its liver disease program at The Liver Meeting 2021. The preclinical studies of SZN-043 demonstrated improved liver metabolic function in mice, with promising non-invasive serum markers for Wnt pathway activation and liver regeneration. Highlights include serum alkaline phosphatase increases, indicating target engagement, and an early increase in circulating angiogenin as a potential biomarker for liver regeneration. These findings support Surrozen's progress towards Phase 1 clinical trials.
Surrozen, a biotechnology firm listed on NASDAQ under the ticker SRZN, announced that CEO Craig Parker will speak at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 a.m. ET. The event will be accessible via a live webcast on the Surrozen website, with an archived replay available later.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, which is crucial for organ development and regeneration. Their proprietary technology aims to address various degenerative diseases and tissue injuries.
FAQ
What is the current stock price of Surrozen Common (SRZN)?
What is the market cap of Surrozen Common (SRZN)?
What is Surrozen, Inc.?
What is SZN-043?
Who are the founders of Surrozen?
What is SZN-413?
What is the Wnt signaling pathway?
How is Surrozen positioned financially?
What are the potential applications of Surrozen's technologies?
What recent achievements has Surrozen announced?
What should investors know about Surrozen's forward-looking statements?
How can one apply for a career at Surrozen?
